Deals in Depth: April 2009
Executive Summary
Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries includes these highlights from February 2009: Pharmaceutical alliance money was weak: the biggest deal of the month was Novartis' $150mm license to Portola's Phase II cardio candidate elinogrel. In M&A, Lundbeck was on top with its takeover of spec pharma Ovation, expanding the European company's neurology drug portfolio in the US. Meanwhile, Beckman Coulter improved its position in the chemistry testing market by buying Olympus' diagnostic systems unit. And Medtronic made two major cardiovascular acquisitions: Ventor and CoreValve. Finally, pharmaceutical financing tripled three times since January to $1.6bn thanks to more than $1bn in public offerings including $684mm netted by BMS, which sold 15% of Mead Johnson through an IPO--the first in the Rx space in one year--as well as Vertex's $314mm FOPO.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.